company background image
4168

GlycoNex Incorporation TPEX:4168 Stock Report

Last Price

NT$25.85

Market Cap

NT$2.5b

7D

-6.8%

1Y

-11.8%

Updated

15 May, 2022

Data

Company Financials
4168 fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

4168 Stock Overview

GlycoNex Incorporation develops cancer drugs using glycosphingolipid antigen and human monoclonal antibody technologies in Taiwan.

GlycoNex Incorporation Competitors

 

 

 

 

 

 

 

 

 

 

 

 

Price History & Performance

Summary of all time highs, changes and price drops for GlycoNex Incorporation
Historical stock prices
Current Share PriceNT$25.85
52 Week HighNT$34.20
52 Week LowNT$23.60
Beta1.16
1 Month Change-13.83%
3 Month Change-8.50%
1 Year Change-11.78%
3 Year Change23.98%
5 Year Change-7.01%
Change since IPO-46.55%

Recent News & Updates

Mar 26
Here's Why We're Not At All Concerned With GlycoNex Incorporation's (GTSM:4168) Cash Burn Situation

Here's Why We're Not At All Concerned With GlycoNex Incorporation's (GTSM:4168) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. Indeed, GlycoNex...

Shareholder Returns

4168TW BiotechsTW Market
7D-6.8%-5.1%-3.4%
1Y-11.8%9.1%0.7%

Return vs Industry: 4168 underperformed the TW Biotechs industry which returned 9.1% over the past year.

Return vs Market: 4168 underperformed the TW Market which returned 0.7% over the past year.

Price Volatility

Is 4168's price volatile compared to industry and market?
4168 volatility
4168 Average Weekly Movement4.9%
Biotechs Industry Average Movement5.3%
Market Average Movement4.6%
10% most volatile stocks in TW Market8.3%
10% least volatile stocks in TW Market2.1%

Stable Share Price: 4168 is not significantly more volatile than the rest of TW stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: 4168's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2001n/aMei-Chun Yanghttps://www.glyconex.com.tw

GlycoNex Incorporation develops cancer drugs using glycosphingolipid antigen and human monoclonal antibody technologies in Taiwan. Its technology platform enables glycan-directed cancer therapy and analytical tools for glycosylation. The company develops GNX102, a humanized antibody for cancer; and GNX201, GNX202, GNX203, and GNX204 for various solid tumors.

GlycoNex Incorporation Fundamentals Summary

How do GlycoNex Incorporation's earnings and revenue compare to its market cap?
4168 fundamental statistics
Market CapNT$2.52b
Earnings (TTM)-NT$172.49m
Revenue (TTM)NT$5.48m

460.3x

P/S Ratio

-14.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
4168 income statement (TTM)
RevenueNT$5.48m
Cost of RevenueNT$2.01m
Gross ProfitNT$3.46m
Other ExpensesNT$175.95m
Earnings-NT$172.49m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-1.77
Gross Margin63.21%
Net Profit Margin-3,150.56%
Debt/Equity Ratio0.0%

How did 4168 perform over the long term?

See historical performance and comparison

Valuation

Is GlycoNex Incorporation undervalued compared to its fair value and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry


1.85x

Price to Book (PB) ratio

Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate 4168's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 4168's fair value for valuation analysis.


Price To Earnings Ratio

PE vs Industry: 4168 is unprofitable, so we can't compare its PE Ratio to the TW Biotechs industry average.

PE vs Market: 4168 is unprofitable, so we can't compare its PE Ratio to the TW market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 4168's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 4168 is good value based on its PB Ratio (1.9x) compared to the TW Biotechs industry average (3.8x).


Future Growth

How is GlycoNex Incorporation forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


125.3%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as GlycoNex Incorporation has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has GlycoNex Incorporation performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-3.4%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: 4168 is currently unprofitable.

Growing Profit Margin: 4168 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 4168 is unprofitable, and losses have increased over the past 5 years at a rate of 3.4% per year.

Accelerating Growth: Unable to compare 4168's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 4168 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-29%).


Return on Equity

High ROE: 4168 has a negative Return on Equity (-12.69%), as it is currently unprofitable.


Financial Health

How is GlycoNex Incorporation's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: 4168's short term assets (NT$358.7M) exceed its short term liabilities (NT$27.2M).

Long Term Liabilities: 4168's short term assets (NT$358.7M) exceed its long term liabilities (NT$8.9M).


Debt to Equity History and Analysis

Debt Level: 4168 is debt free.

Reducing Debt: 4168 had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 4168 has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: 4168 has sufficient cash runway for 2.2 years if free cash flow continues to grow at historical rates of 23% each year.


Dividend

What is GlycoNex Incorporation current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate 4168's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 4168's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 4168's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 4168's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: 4168 is not paying a notable dividend for the TW market.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as 4168 has not reported any payouts.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?


CEO

Mei-Chun Yang

no data

Tenure

Dr. Mei-Chun Yang serves as the President and Chief Executive Officer at GlycoNex Incorporation. She served as Director of Glyconex Incorporation.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

GlycoNex Incorporation's employee growth, exchange listings and data sources


Key Information

  • Name: GlycoNex Incorporation
  • Ticker: 4168
  • Exchange: TPEX
  • Founded: 2001
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: NT$2.520b
  • Shares outstanding: 97.48m
  • Website: https://www.glyconex.com.tw

Location

  • GlycoNex Incorporation
  • No. 97, Xintai 5th Road
  • 8th Floor
  • New Taipei City
  • 221
  • Taiwan

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/15 00:00
End of Day Share Price2022/05/13 00:00
Earnings2021/12/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.